Tenderwize
Back to tender search

Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V mit dem Wirkstoff Adalimumab

GWQ ServicePlus AG·Düsseldorf, Germany·Deadline Nov 10, 2026 · 126 days left·Open·Supplies
Sign up to saveTED notice
Structured notice only
Original notice title

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V mit dem Wirkstoff Adalimumab

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Why this score?

Opportunity

50 / 100

Complexity

30 / 100

Risk factors

No contract value or volume information is provided. Companies cannot estimate potential revenue.

Key procurement documents (vertragsunterlagen, annexes) are available only on the buyer's portal and were not analyzed...

No procurement documents available

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Dec 2026
  • Non-exclusive discount agreements for the active substance Adalimumab
  • Agreements to be concluded between GWQ ServicePlus AG (representing multiple German health insurance funds) and pharmaceutical companies
Show full summary

Non-exclusive discount agreement under §130a Abs. 8 SGB V for the active substance Adalimumab, organized by GWQ ServicePlus AG on behalf of multiple German statutory health insurance funds. The procedure is open to all interested pharmaceutical companies (accession model) with contract start 01.01.2025. No estimated value provided. Submission deadline: 10.11.2026 (postal). Award based on price only.

Risks

No contract value or volume information is provided. Companies cannot estimate potential revenue.

Key procurement documents (vertragsunterlagen, annexes) are available only on the buyer's portal and were not analyzed...

No procurement documents available

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Pharmaceutical company must hold marketing authorization for Adalimumab (proof from AMIce database)

Administrative

  • Submit signed contract in duplicate
  • Submit signed self-declaration (Annex 3)

Requirements may be incomplete.

Award Criteria

Lot 1

Price criterion

Buyer

Name

GWQ ServicePlus AG

Location

Düsseldorf, DEU

Buyer profile

Open profile

Identifier

DE258895210

Activity

Health

Lots (1)

LOT-0000

Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V mit dem Wirkstoff Adalimumab

Non-exclusive discount agreements for Adalimumab. Open accession model – any pharmaceutical company can join at any time during contract term. Requires submission of signed contract, proof of marketing authorization, self-declaration (Annex 3), list of PZNs (Annex 2), and EU regulation self-declaration (Annex 5).

SuppliesEU fundedElectronic submission

Location

DEA11, Germany

Duration

Dec 2024 - Dec 2026

Category

Pharmaceutical products

Selection criteria

Price

Deadline

Deadline Nov 10, 2026

Procurement Details

Publication date
10 Nov 2024
Notice type
Contract notice — standard
Languages
German

Reference metadata

Notice subtype
16
Notice version
1
Legal basis
32014L0024

Reference IDs

Tender ID
686479-2024

Similar tenders

Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Ganirelix (ATC-Code: H01CC01).

DEUJun 27

Czechia – Pharmaceutical products – Léčivý přípravek ATC skupiny R03DX05 s účinnou látkou OMALIZUMAB

CZEAug 3

Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V über Arzneimittel mit dem Wirkstoff Denosumab Xgeva (ATC-Code nach WHO: M05BX04)

DEUJul 31

Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit der Wirkstoffkombination aus Formoterol und Beclometason, ausgenommen Dosieraerosole mit der Wirkstärke 100µg/6µg (ATC-Code: R03AK08).

DEUJun 27

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.

DEUDec 31

Moldova – Pharmaceutical products – Achiziționarea centralizată a Reagenților pentru Investigații Clinice, Hematologice și PATOLOGICE conform necesităților IMSP - beneficiari pentru anul 2027

MDAAug 4